(SEATTLE), December 21, 2020 -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced its partnership with Laboratoire Pierre Fabre to manufacture ER-004 – an intra-amniotic drug that will pioneer the treatment of a rare and debilitating genetic disorder. AGC Biologics will manufacture GMP material for the next stage of clinical trial.
David Self
Recent Posts by David Self:
Pierre Fabre Selects AGC Biologics as CDMO to Manufacture the Orphan Drug ER-004
by David Self Published on 12/21/20 7:00 AM News
Learn More
Follow Us
Content not found